Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8829000
APP PUB NO 20130225572A1
SERIAL NO

13617683

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I)

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASKA PHARMACEUTICAL CO LTDTOKYO TOKYO METROPOLIS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gotanda, Kotaro Kawasaki, JP 10 78
Kawade, Kenji Kawasaki, JP 3 42
Kobayashi, Hideo Saitama, JP 434 4833
Nakano, Youichi Hachioji, JP 19 133
Okada, Makoto Inagi, JP 98 1232
Sato, Shuichiro Komae, JP 12 78
Shinbo, Atsushi Niiza, JP 9 102

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 9, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00